FOLH1 and neoplasm: Since therapies targeting both PSMA and PARP1 pathways are now available for mCRPC, we sought in this study to investigate the relationship between [68Ga]PSMA and [18F]PARPi uptake by detecting and quantifying PARPi versus [68Ga]PSMA uptake in different tumor lesions in mCRPC patients using PET/CT scans.